BACKGROUND: Several (99m)Tc-labeled agents that are not approved by the U.S. Food and Drug Administration are used for lymphatic mapping. A new low-molecular-weight mannose receptor-based, reticuloendothelial cell-directed, (99m)Tc-labeled lymphatic imaging agent, (99m)Tc-tilmanocept, was used for lymphatic mapping of sentinel lymph nodes (SLNs) from patients with primary breast cancer or melanoma malignancies. This novel molecular species provides the basis for potentially enhanced SLN mapping reliability. METHODS: In a prospectively planned, open-label phase 2 clinical study, (99m)Tc-tilmanocept was injected into breast cancer and cutaneous melanoma patients before intraoperative lymphatic mapping. Injection technique, preoperative lymphoscintigraphy (LS), and intraoperative lymphatic mapping with a handheld gamma detection probe were performed by investigators per standard practice. RESULTS: Seventy-eight patients underwent (99m)Tc-tilmanocept injection and were evaluated (47 melanoma, 31 breast cancer). For those whom LS was performed (55 patients, 70.5%), a (99m)Tc-tilmanocept hot spot was identified in 94.5% of LS patients before surgery. Intraoperatively, (99m)Tc-tilmanocept identified at least one regional SLN in 75 (96.2%) of 78 patients: 46 (97.9%) of 47 in melanoma and 29 (93.5%) of 31 in breast cancer cases. Tissue specificity of (99m)Tc-tilmanocept for lymph nodes was 100%, displaying 95.1% mapping sensitivity by localizing in 173 of 182 nodes removed during surgery. The overall proportion of (99m)Tc-tilmanocept-identified nodes that contained metastatic disease was 13.7%. Five procedure-related serious adverse events occurred, none related to (99m)Tc-tilmanocept. CONCLUSIONS: Our results demonstrate the safety and efficacy of (99m)Tc-tilmanocept for use in intraoperative lymphatic mapping. The high intraoperative localization and lymph node specificity of (99m)Tc-tilmanocept and the identification of metastatic disease within the nodes suggest SLNs are effectively identified by this novel mannose receptor-targeted molecule.
BACKGROUND: Several (99m)Tc-labeled agents that are not approved by the U.S. Food and Drug Administration are used for lymphatic mapping. A new low-molecular-weight mannose receptor-based, reticuloendothelial cell-directed, (99m)Tc-labeled lymphatic imaging agent, (99m)Tc-tilmanocept, was used for lymphatic mapping of sentinel lymph nodes (SLNs) from patients with primary breast cancer or melanoma malignancies. This novel molecular species provides the basis for potentially enhanced SLN mapping reliability. METHODS: In a prospectively planned, open-label phase 2 clinical study, (99m)Tc-tilmanocept was injected into breast cancer and cutaneous melanomapatients before intraoperative lymphatic mapping. Injection technique, preoperative lymphoscintigraphy (LS), and intraoperative lymphatic mapping with a handheld gamma detection probe were performed by investigators per standard practice. RESULTS: Seventy-eight patients underwent (99m)Tc-tilmanocept injection and were evaluated (47 melanoma, 31 breast cancer). For those whom LS was performed (55 patients, 70.5%), a (99m)Tc-tilmanocept hot spot was identified in 94.5% of LS patients before surgery. Intraoperatively, (99m)Tc-tilmanocept identified at least one regional SLN in 75 (96.2%) of 78 patients: 46 (97.9%) of 47 in melanoma and 29 (93.5%) of 31 in breast cancer cases. Tissue specificity of (99m)Tc-tilmanocept for lymph nodes was 100%, displaying 95.1% mapping sensitivity by localizing in 173 of 182 nodes removed during surgery. The overall proportion of (99m)Tc-tilmanocept-identified nodes that contained metastatic disease was 13.7%. Five procedure-related serious adverse events occurred, none related to (99m)Tc-tilmanocept. CONCLUSIONS: Our results demonstrate the safety and efficacy of (99m)Tc-tilmanocept for use in intraoperative lymphatic mapping. The high intraoperative localization and lymph node specificity of (99m)Tc-tilmanocept and the identification of metastatic disease within the nodes suggest SLNs are effectively identified by this novel mannose receptor-targeted molecule.
Authors: Borys R Krynyckyi; Chun K Kim; Martin R Goyenechea; Peggy T Chan; Zhuang-Yu Zhang; Josef Machac Journal: Radiographics Date: 2004 Jan-Feb Impact factor: 5.333
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Giuliano Mariani; Marco Gipponi; Luciano Moresco; Giuseppe Villa; Mirco Bartolomei; Giovanni Mazzarol; Maria Claudia Bagnara; Antonella Romanini; Ferdinando Cafiero; Giovanni Paganelli; H William Strauss Journal: J Nucl Med Date: 2002-06 Impact factor: 10.057
Authors: Scott J Ellner; Carl K Hoh; David R Vera; Denise D Darrah; Gery Schulteis; Anne M Wallace Journal: Nucl Med Biol Date: 2003-11 Impact factor: 2.408
Authors: Michael A Liss; Salman Farshchi-Heydari; Zhengtao Qin; Sean A Hickey; David J Hall; Christopher J Kane; David R Vera Journal: J Nucl Med Date: 2014-07-14 Impact factor: 10.057
Authors: Christina Bluemel; Ken Herrmann; Francesco Giammarile; Omgo E Nieweg; Julien Dubreuil; Alessandro Testori; Riccardo A Audisio; Odysseas Zoras; Michael Lassmann; Annette H Chakera; Roger Uren; Sotirios Chondrogiannis; Patrick M Colletti; Domenico Rubello Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-25 Impact factor: 9.236
Authors: Zhengtao Qin; David J Hall; Michael A Liss; Carl K Hoh; Christopher J Kane; Anne M Wallace; David R Vera Journal: J Biomed Opt Date: 2013-10 Impact factor: 3.170
Authors: Christy Y Chai; Jonathan S Zager; Margaret M Szabunio; Suroosh S Marzban; Alec Chau; Robert M Rossi; Vernon K Sondak Journal: Ann Surg Oncol Date: 2011-12-23 Impact factor: 5.344
Authors: Michael A Liss; Sean P Stroup; Zhengtao Qin; Carl K Hoh; David J Hall; David R Vera; Christopher J Kane Journal: Urology Date: 2014-08-16 Impact factor: 2.649
Authors: Markella V Zanni; Mabel Toribio; Moses Q Wilks; Michael T Lu; Tricia H Burdo; Joshua Walker; Patrick Autissier; Borek Foldyna; Lauren Stone; Amanda Martin; Fred Cope; Bonnie Abbruzzese; Thomas Brady; Udo Hoffmann; Kenneth C Williams; Georges El-Fakhri; Steven K Grinspoon Journal: J Infect Dis Date: 2017-04-15 Impact factor: 5.226
Authors: Abul K Azad; Murugesan V S Rajaram; Wendy L Metz; Frederick O Cope; Michael S Blue; David R Vera; Larry S Schlesinger Journal: J Immunol Date: 2015-07-22 Impact factor: 5.422
Authors: Derek K Emerson; Karl K Limmer; David J Hall; Sung-Ho Han; William C Eckelman; Christopher J Kane; Anne M Wallace; David R Vera Journal: Radiology Date: 2012-07-02 Impact factor: 11.105